Abstracts

Citation

Sharon Appelbaum Nachman, M.D., Myron Levin, M.D., Lin-Ye Song, Ph.D., Adriana Weinberg, M.D., Robert Walker, M.D. Phase I/II randomized trial of the safety and immunogenicity of cold adapted influenza vaccine (CAIV) vs. inactivated influenza vaccine (IAIV) in HIV infected (HIV+) children; PACTG 1057. Presented at: 13th Conference on Retroviruses and Opportunistic Infections.

Citation

Ross E. McKinney, Jr., M.D., Mobeen H. Rathore, M.D., ChengCheng Hu, Ph.D., Paula Britto, M.S., Ruth E. Dickover, Ph.D., Diane Claire Smith, B.A., M.T. (A.S.C.P.), Adriana Weinberg, M.D. Phase I/II study of a once-daily regimen of emtricitabine, didanosine, and efavirenz in HIV-infected, therapy-naive children and adolescents: PACTG proctol 1021. Presented at: 13th Conference on Retroviruses and Opportunistic Infections.

Citation

Meyers T, Krogstad P, Samson P, Acosta EP, Moye J, Townley E, Bradford S, Marillo L, Hovind L, Sise T, Teppler H, Dittmer S, Fairlie L, Hesseling AC, Cotton MF. Phase I/II study of a raltegravir-containing regimen in HIV-infected children with TB. Presented at: CROI 2018; 2018 Mar 05.

Citation

Wayne M. Dankner, M.D. Phase II/III, Randomized, Double-Blind Trial to Compare Atovaquone Plus Azithromycin (AT/AZ) to Trimethoprim-Sulfamethoxazole (TMP-SMX) in the Prevention of Multiple Opportunistic Pathogen Infections (MOPPS) in HIV-Infected Children.

Citation

Phase III Randomized Trial of the Safety and Efficacy of Three Neonatal Antiretroviral Regimens for Prevention of Intrapartum. Presented at: 18th Conference on Retroviruses & Opportunistic Infections.

Citation

Alejandro Dorenbaum, M.D., John L. Sullivan, M.D., Richard D. Gelber, Ph.D., Lynne M. Mofenson, M.D., F.A.A.P., Mary Culnane, C.R.N.P., M.S., Coleen K. Cunningham, M.D., Gina M. Brown, M.D., G. Brown, Karen P. Beckerman, M.D., Kevin Dransfield. Phase III, Randomized, Blinded Study Of Single-Dose Intrapartum/Neonatal Nevirapine To Reduce Mother To Infant HIV Transmission.

Citation

T Ruel, E Acosta, R Singh, C Alvero, K George, S Popson, M Bartlett, A Buchanan, C Brothers, L Koech, T Vhembo, R Hazra, E Townley, A Wiznia, P1093 team. PK and 4-week outcomes of dolutegravir dispersible tablets in HIV-infected children. Presented at: CROI 2019; 2019 Mar 07.

Citation

Jeremiah Momper, Hardik Chandasana, Jiajia Wang, Benjamin Johnston, Sarah Bradford, Dwight Yin, Tara Deyampert, Ann Buchanan, Edward P. Acosta, Mark Mirochnick, Kathleen Powis, Diana Clarke. PK and Safety of Chronic Dolutegravir Administration in Neonates Exposed to HIV-1 (IMPAACT 2023). Presented at: CROI 2025; 2025 Mar 11.

Citation

Elizabeth Livingston, M.D., Sheran Patel, D.O., Jashvant D. Unadkat, Ph.D., Ross E. McKinney, Jr., M.D., Arlene D. Bardeguez, M.D., M.P.H., F.A.C.O.G., Mary Jo O'Sullivan, M.D. Placental Transfer of Didanosine (ddI) and Initial Evaluation of Didanosine Toxicity in HIV-1 Infected Pregnant Women and their Offspring.

Citation

S Kapetanovic, MJ Giganti, JC Lindsey, PA Sirois, G Montepiedra, A Agwu, J Canniff, MJ Boivin, MJ Abzug, A Weinberg for the IMPAACT P1060 and P1104s teams. Plasma Factors Associated with Neurodevelopment in Children with Perinatal HIV. Presented at: CROI 2020.